Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TVTX
stocks logo

TVTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
143.04M
+91.27%
0.220
-146.81%
133.51M
+63.35%
0.072
-137.72%
153.11M
+33.78%
0.262
+101.28%
Estimates Revision
The market is revising Upward the revenue expectations for Travere Therapeutics, Inc. (TVTX) for FY2025, with the revenue forecasts being adjusted by 19.86% over the past three months. During the same period, the stock price has changed by 63.26%.
Revenue Estimates for FY2025
Revise Upward
up Image
+19.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-505.83%
In Past 3 Month
Stock Price
Go Up
up Image
+63.26%
In Past 3 Month
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 35.330
sliders
Low
31.00
Averages
40.09
High
49.00
Current: 35.330
sliders
Low
31.00
Averages
40.09
High
49.00
Piper Sandler
Allison Bratzel
Neutral
maintain
$26 -> $35
2025-11-04
Reason
Piper Sandler
Allison Bratzel
Price Target
$26 -> $35
2025-11-04
maintain
Neutral
Reason
Piper Sandler analyst Allison Bratzel raised the firm's price target on Travere Therapeutics to $35 from $26 and keeps a Neutral rating on the shares. The firm notes Filspari had a strong Q3, with U.S. revenue of $90.9M coming in about $12M above consensus, representing +26% quarter-over-quarter growth and an impressive 155% year-over-year growth. Piper sees the upcoming regulatory decision for FSGS as the primary near-term driver for shares, with regulatory uncertainty leading the firm to remain on the sidelines.
TD Cowen
Tyler Van Buren
Buy
maintain
$30 -> $40
2025-10-31
Reason
TD Cowen
Tyler Van Buren
Price Target
$30 -> $40
2025-10-31
maintain
Buy
Reason
TD Cowen analyst Tyler Van Buren raised the firm's price target on Travere Therapeutics to $40 from $30 and keeps a Buy rating on the shares. The firm said Q3 Filspari sales of $91MM (+26% Q/Q) led to an impressive 15% beat over consensus, underscoring strong demand, PSF pull-through, and persistence.
Citi
Yigal Nochomovitz
Buy
maintain
$34 -> $48
2025-10-31
Reason
Citi
Yigal Nochomovitz
Price Target
$34 -> $48
2025-10-31
maintain
Buy
Reason
Citi analyst Yigal Nochomovitz raised the firm's price target on Travere Therapeutics to $48 from $34 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Travere. The firm expects FDA approval by the action date of January 13, 2026, for Filspari for the treatment of focal segmental glomerulosclerosis. Citi believes "everything seems to be moving in a positive direction" for Travere following the Q3 report.
Evercore ISI
Outperform
to
NULL
downgrade
$45 -> $35
2025-10-01
Reason
Evercore ISI
Price Target
$45 -> $35
2025-10-01
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Travere Therapeutics to $35 from $45 and keeps an Outperform rating on the shares. All eyes are on the FSGS PDUFA on January 13, 2026, given that this has "implications for the whole renal field," according to the analyst, who sees this as an up 30%-35% or down 60%-65% event for Travere.
Stifel
Hold
maintain
$20 -> $25
2025-09-12
Reason
Stifel
Price Target
$20 -> $25
2025-09-12
maintain
Hold
Reason
Stifel raised the firm's price target on Travere Therapeutics to $25 from $20 and keeps a Hold rating on the shares following the announcement that FDA no longer plans to hold an advisory committee meeting for the sparsentan sNDA in focal segmental glomerulosclerosis. While the firm finds this "unexpected," it notes that more recent precedent from FDA AdCom cancelations have been taken as positive indicators and is updating its model to reflect 90% odds of success of approval.
Wells Fargo
Mohit Bansal
Overweight
maintain
$27 -> $35
2025-09-11
Reason
Wells Fargo
Mohit Bansal
Price Target
$27 -> $35
2025-09-11
maintain
Overweight
Reason
Wells Fargo analyst Mohit Bansal raised the firm's price target on Travere Therapeutics to $35 from $27 and keeps an Overweight rating on the shares to reflect increased confidence in focal segmental glomerulosclerosis approval. IgAN momentum also provides support, but the next critical catalyst and inflection point could be the January 13th PDUFA for FSGS, the firm adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Travere Therapeutics Inc (TVTX.O) is 34.74, compared to its 5-year average forward P/E of 37.35. For a more detailed relative valuation and DCF analysis to assess Travere Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
37.35
Current PE
34.74
Overvalued PE
339.13
Undervalued PE
-264.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
86.26
Undervalued EV/EBITDA
-62.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.33
Current PS
0.00
Overvalued PS
7.31
Undervalued PS
3.36
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TVTX News & Events

Events Timeline

(ET)
2025-11-06
11:06:47
Travere Therapeutics reveals findings from Phase 3 DUPLEX trial of FILSPARI
select
2025-10-30 (ET)
2025-10-30
16:05:54
Travere Therapeutics Announces Q3 EPS of 29 Cents, Exceeding Consensus Estimate of 9 Cents
select
2025-10-17 (ET)
2025-10-17
09:10:06
Travere Therapeutics to Showcase Abstracts at ASN Kidney Week
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-30Benzinga
The Insider Report: Holiday Purchases Followed the Market Dip

  • Market Performance: The S&P 500 and Dow Jones reached record highs last week, with the S&P up 3.73% and the Dow up 3.18%, while the Nasdaq saw a 4.91% increase, marking its second-highest weekly close in history. The consumer discretionary sector rebounded significantly, and silver hit an all-time high.

  • Travere Therapeutics Overview: Travere Therapeutics (TVTX) is positioned for a 71% return potential, focusing on innovative treatments for rare kidney diseases. The company reported strong revenue growth and is set to expand its market with pivotal regulatory advancements for its drug FILSPARI.

  • Outfront Media Insights: Outfront Media (OUT) is expected to yield a 31% return potential, benefiting from a resurgence in out-of-home advertising. The company reported robust Q3 revenues and is enhancing its digital billboard portfolio, positioning itself for sustained growth amid economic recovery.

  • Market Catalysts and Trends: The upcoming holiday season is seen as a prime time for stock purchases, especially following a recent market correction. Analysts are monitoring key ratios related to market liquidity and sector performance, with a focus on the semiconductor and Nasdaq relationship as indicators of market health.

[object Object]
Preview
5.0
11-18NASDAQ.COM
Reasons Behind the Fund's Decision to Reduce Its $161 Million Stake in Travere Following a 100% Surge

  • Armistice Capital's Share Sale: Armistice Capital sold 2,152,000 shares of Travere Therapeutics for approximately $29.3 million in Q3, reducing its stake to 6.7 million shares valued at $160.7 million, which now represents 2% of the fund's assets.

  • Performance of Travere Therapeutics: Travere Therapeutics has seen a significant increase in its stock price, up 100% over the past year, and reported strong financial results with total revenue reaching $164.9 million, driven by a 155% increase in U.S. sales of its product FILSPARI.

  • Investment Strategy: Despite the sale, Armistice remains heavily invested in Travere, indicating disciplined portfolio management rather than a shift in investment thesis, especially with upcoming regulatory decisions expected to impact the company's future.

  • Market Context: The biopharmaceutical sector, particularly companies like Travere that focus on rare diseases, is experiencing growth due to increasing commercial uptake and improving profitability, making it an attractive area for long-term investors.

[object Object]
Preview
1.0
11-05Newsfilter
Travere Therapeutics Set to Attend Upcoming Investor Conferences

  • Upcoming Investor Conferences: Travere Therapeutics will participate in several investor conferences, including Guggenheim's Healthcare Innovation Conference on November 11, 2025, and the Jefferies Global Healthcare Conference on November 18, 2025.

  • Webcast Availability: Live webcasts of the presentations will be available on Travere's Investor page, with replays accessible for up to 30 days after each event.

  • Company Mission: Travere Therapeutics is dedicated to helping patients with rare diseases by developing and delivering life-changing therapies, emphasizing the urgency for treatment options.

  • Contact Information: For investor inquiries, Travere provides contact details including a phone number and email for both investor relations and media relations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Travere Therapeutics Inc (TVTX) stock price today?

The current price of TVTX is 35.33 USD — it has increased 1.38 % in the last trading day.

arrow icon

What is Travere Therapeutics Inc (TVTX)'s business?

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

arrow icon

What is the price predicton of TVTX Stock?

Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Travere Therapeutics Inc (TVTX)'s revenue for the last quarter?

Travere Therapeutics Inc revenue for the last quarter amounts to 164.86M USD, increased 162.11 % YoY.

arrow icon

What is Travere Therapeutics Inc (TVTX)'s earnings per share (EPS) for the last quarter?

Travere Therapeutics Inc. EPS for the last quarter amounts to 0.25 USD, decreased -135.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Travere Therapeutics Inc (TVTX)'s fundamentals?

The market is revising Upward the revenue expectations for Travere Therapeutics, Inc. (TVTX) for FY2025, with the revenue forecasts being adjusted by 19.86% over the past three months. During the same period, the stock price has changed by 63.26%.
arrow icon

How many employees does Travere Therapeutics Inc (TVTX). have?

Travere Therapeutics Inc (TVTX) has 385 emplpoyees as of December 05 2025.

arrow icon

What is Travere Therapeutics Inc (TVTX) market cap?

Today TVTX has the market capitalization of 3.16B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free